GVK inks deal with FDA for 'drug repositioning'

India's GVK Biosciences has added another big name to its list of clients, licensing its proprietary databases to help the FDA identify alternative indications for drugs already on the market, seeing if they can treat neglected and orphan diseases. GVK's databases contain more than 6.5 million compounds, and over the past year, the company has linked up with Onconova, Endo Pharmaceuticals ($ENDP) and the University of Dundee. More

Suggested Articles

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

After delisting from the New York Stock Exchange, WuXi AppTec has received regulatory approval to be listed in Shanghai.

Raxone is currently in a phase 3 study on DMD patients who are taking glucocorticoids.